FORMYCON AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.9 EUR | +4.85% |
|
+12.10% | -6.65% |
| 18/06 | Borse Frankfurt-News: Many winners and many losers (second-line stocks) | DP |
| 13/06 | Formycon Starts Clinical Trials of Keytruda Biosimilar Candidate for Skin Cancer Therapy | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 319 | 530 | 651.7 | 1,309 | 904.6 | 923.6 | - | - |
| Enterprise Value (EV) 1 | 296.6 | 487.8 | 626.6 | 1,648 | 904.6 | 914.1 | 914.5 | 853.9 |
| P/E ratio | -139 x | -98.4 x | -48.4 x | 33.4 x | 11.9 x | -46.4 x | 179 x | 9.95 x |
| Yield | - | - | - | - | - | - | 0.47% | - |
| Capitalization / Revenue | 9.41 x | 15.5 x | 17.6 x | 30.8 x | 11.6 x | 15.4 x | 10.9 x | 4.92 x |
| EV / Revenue | 8.75 x | 14.3 x | 17 x | 38.8 x | 11.6 x | 15.2 x | 10.8 x | 4.55 x |
| EV / EBITDA | -212 x | -101 x | -50.6 x | -104 x | 596 x | -47.5 x | 55.7 x | 7.41 x |
| EV / FCF | -123 x | -86.1 x | -42.1 x | -36.1 x | - | -11.1 x | -33 x | 13.1 x |
| FCF Yield | -0.81% | -1.16% | -2.38% | -2.77% | - | -9% | -3.03% | 7.62% |
| Price to Book | 6.62 x | 8.57 x | 11.6 x | 3.67 x | - | 1.87 x | 1.82 x | 1.52 x |
| Nbr of stocks (in thousands) | 10,000 | 10,000 | 11,047 | 15,130 | 16,039 | 17,660 | - | - |
| Reference price 2 | 31.90 | 53.00 | 59.00 | 86.50 | 56.40 | 52.30 | 52.30 | 52.30 |
| Announcement Date | 18/05/20 | 17/05/21 | 18/05/22 | 27/04/23 | 25/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 33.9 | 34.23 | 36.96 | 42.5 | 77.7 | 60.04 | 84.85 | 187.6 |
| EBITDA 1 | -1.4 | -4.81 | -12.39 | -15.87 | 1.518 | -19.25 | 16.43 | 115.3 |
| EBIT 1 | -2.3 | -5.725 | -13.33 | -17.73 | -0.369 | -23.48 | -3.788 | 98.5 |
| Operating Margin | -6.78% | -16.73% | -36.07% | -41.72% | -0.47% | -39.1% | -4.46% | 52.49% |
| Earnings before Tax (EBT) 1 | -2.291 | -5.923 | -13.47 | 36.6 | 79.07 | -15.51 | 6.75 | 112.1 |
| Net income 1 | -2.293 | -5.926 | -13.48 | 35.99 | 75.8 | -18.51 | 5.085 | 93 |
| Net margin | -6.76% | -17.31% | -36.46% | 84.69% | 97.55% | -30.83% | 5.99% | 49.56% |
| EPS 2 | -0.2293 | -0.5387 | -1.218 | 2.590 | 4.720 | -1.127 | 0.2929 | 5.257 |
| Free Cash Flow 1 | -2.403 | -5.662 | -14.88 | -45.64 | - | -82.3 | -27.7 | 65.08 |
| FCF margin | -7.09% | -16.54% | -40.26% | -107.39% | - | -137.09% | -32.65% | 34.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 56.46% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 69.98% |
| Dividend per Share 2 | - | - | - | - | - | - | 0.2433 | - |
| Announcement Date | 18/05/20 | 17/05/21 | 18/05/22 | 27/04/23 | 25/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 17.7 | 14 | 14 | 14 | 17 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -6 | -5.4 | -5.4 | -5.4 | - |
| Operating Margin | - | -33.9% | -38.57% | -38.57% | -38.57% | - |
| Earnings before Tax (EBT) 1 | - | -6 | -4.95 | -4.95 | -4.95 | - |
| Net income 1 | 1.804 | -6 | -4.95 | -4.95 | -4.95 | - |
| Net margin | - | -33.9% | -35.36% | -35.36% | -35.36% | - |
| EPS 2 | 0.1130 | -0.3700 | -0.2900 | -0.2800 | -0.2800 | -0.2000 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 30/08/23 | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 339 | - | - | - | - |
| Net Cash position 1 | 22.4 | 42.2 | 25.2 | - | - | 9.53 | 9.12 | 69.7 |
| Leverage (Debt/EBITDA) | - | - | - | -21.36 x | - | - | - | - |
| Free Cash Flow 1 | -2.4 | -5.66 | -14.9 | -45.6 | - | -82.3 | -27.7 | 65.1 |
| ROE (net income / shareholders' equity) | -5.63% | -10.2% | -21.7% | 17.5% | - | -4.3% | 1.68% | 15% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 4.820 | 6.190 | 5.070 | 23.60 | - | 28.00 | 28.70 | 34.40 |
| Cash Flow per Share 2 | - | -0.4600 | -1.280 | -1.380 | - | -1.520 | 1.740 | 5.990 |
| Capex 1 | 0.92 | 0.56 | 0.7 | 26.8 | - | 63.7 | 61.5 | 60.5 |
| Capex / Sales | 2.72% | 1.63% | 1.9% | 62.97% | - | 106.03% | 72.51% | 32.23% |
| Announcement Date | 18/05/20 | 17/05/21 | 18/05/22 | 27/04/23 | 25/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
52.3
EUR
Average target price
85.56
EUR
Spread / Average Target
+63.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.14% | 51.12B | |
| -6.54% | 39.4B | |
| +34.92% | 38.48B | |
| -12.11% | 26.22B | |
| +12.62% | 26.36B | |
| -13.43% | 20.96B | |
| +43.73% | 14.02B | |
| +31.81% | 12.49B | |
| -4.54% | 11.61B |
- Stock Market
- Equities
- FYB Stock
- FYB Stock
- Financials Formycon AG
